Hypertension In Hemodialysis Patients Research Articles

Intervention control of aerobic exercise in maintaining quality of life and pulmonary hypertension in hemodialysis patients.

Pulmonary hypertension is a serious complication in the treatment of maintenance hemodialysis patients, which seriously affects the quality of life of patients and threatens their life safety. Prevention, treatment and improvement of pulmonary hypertension are of great significance to improve the quality of life of patients. To investigate the intervention and control of pedal-powered bicycle in maintaining quality of life and pulmonary hypertension in hemodialysis patients. 73 patients with maintenance hemadialysis combined with pulmonary arterial hypertension at a hemodialysis center in a certain hospital from May 2021 to May 2022 are selected. Patients are divided into two groups, 37 cases in the control group (group C) and 36 cases in the intervention group (group I). Patients are divided into two groups, group C is treated with oral administration of betaglandin sodium combined with routine nursing care. Based on group C, group I conducts power cycling exercises. After treatment, group I patients had higher muscle strength, 36-Item Short Form Health Survey scores, and Kidney Disease Targets Areas scores; The 6-minute walk distance test index level was higher and the Borg score was lower; The group I had lower systolic blood pressure, greater vital capacity, higher positive emotion, lower systolic pulmonary artery pressure index level, higher arterial partial oxygen pressure level, lower pulmonary vascular resistance index level, and higher blood oxygen saturation level [158.91 ± 11.89 vs 152.56 ± 12.81, 1795.01 ± 603.18 vs 1907.20 ± 574.15, 24.00 (22.00, 29.00) vs 24.00 (22.00, 28.00), P < 0.001]. Aerobic exercise combined with Western medicine treatment can effectively improve patients' pulmonary hypertension, alleviate their negative emotions, and enable them to achieve a higher level of quality of life.

Real world treatment of hypertension on hemodialyses-data from large Polish database.

The prevalence of hypertension among patients with end stage kidney disease (ESKD) undergoing hemodialysis (HD) ranges from 72-88% depending on applied diagnostic criteria and chosen method of blood pressure measurement. Despite the guidelines recommending the widespread use of renin angiotensin system blockers (RASB) in patients with kidney disease, their utilization in patients on HD may be suboptimal, especially in patients with preserved diuresis. This hesitance often steams from concern is often due to fear of a decrease in eGFR and a subsequent decrease in diuresis. The aim of this study was to compare clinical characteristics, blood pressure, safety, and hemodialysis adequacy indices in hypertensive HD patients on multiple antihypertensive drug regimens, including diuretic treated with RASB (RASB group) or without RASB (no-RASB) with preserved residual diuresis. We sought to examine the real life use of RASB in hemodialysis patients in relation to their clinical characteristics, blood pressure, safety, and hemodialysis adequacy. From a database of 5879 patients receiving hemodialysis (mean age 65.2±14.2 yrs., 60% of males) of the largest provider of HD in the country, we selected the subgroup treated with at least three antihypertensive medications including diuretics. We compared patients treated with RASB to counterparts without RASB (no-RASB). RASB group has similar age and gender proportions as well as BMI and bioimpedance,compared to counterparts. However, dry body mass was significantly lower in the RASB group (78.1±18.3 kg vs. 80.0±18.2 kg, p&lt;0.017). Prevalence of diabetes mellitus was similar in both groups, but RASB-treated patients have cardiovascular diseases more frequently (70.1% vs. 60.8%; p&lt;0.001). Systolic blood pressure and the number of antihypertensive drugs used were significantly higher in RASB patients than in counterparts (146±16 mmHg vs. 144±15 mmHg; p&lt;0.001 and 4.1±0.9 vs. 3.5±0.5; p&lt;0001 respectively). RASB-treated patients have significantly longer dialysis vintage (52.7±44.4 months vs. 40.2±40.9 months; p&lt;0.001) and dialysis time (722±87.1 min./week vs. 713±93.4 min./week;p&lt;0.017) than counterparts. Serum potassium was slightly but significantly higher in RASB (5.3±0.8 mmol/L vs. 5.1±0.7 mmol/L;p&lt;0.01). In the real world setting, RASB can be safely used in HD patients treated with diuretics with preserved residual diuresis. Given that many HD patients present numerous multimorbidities, RASB should not only be considered as an additional hypotensive drug in poorly controlled hypertension but also in other compelling indications in HD patients. The tendency toward hyperkalemia in HD patients could be effectively managed with appropriate diet and HD prescription adjustments.

#2470 Isolated diastolic hypertension in hemodialysis patients

Abstract Background and Aims Isolated diastolic hypertension (IDH) is relatively rare in the general population (prevalence about 6.5%, Front Cardiovasc Med. 2021;8:810105) and of uncertain etiologic implications. The prevalence of this alteration in the hemodialysis (HD) population and the etiologic implications of IDH have not been studied. Method We investigated the prevalence and the risk for all-cause death and cardiovascular events of isolated diastolic hypertension in a population of 534 HD patients enrolled in 7 centres in 3 European countries (the EURECA-m working group). BP was measured by a golden standard method in this population (48 h ABPM) using well-validated instruments (AAMI/ESH/ISO). Along with recommendations by the European Society of Hypertension guidelines, recordings were made at 15-minute intervals during the day and 30 minutes at night. According to a consensus document by the EURECAm working group (Nephrol Dial Transplant. 2019;34:1542-1548), isolated diastolic hypertension was defined as 48 h diastolic BP &amp;gt; 80 mmHg with a systolic BP &amp;lt;130. Results Among 534 HD patients, thirty-one (5.8%) had isolated diastolic HTN, which is very close to the prevalence estimated in the general population (6.5%). During a mean follow-up of 2.6 years, 138 patients died, 188 had at least one CV event, and 249 experienced the combined event. In univariate analyses, diastolic hypertension was associated with death (HR 0.21; 95% CI: 0.05-0.86, P = 0.03) and the combined outcome of death and CV events (HR 0.42, 95% CI: 0.20-0.88, P = 0.02). However, these associations were no longer significant after adjustment for age and sex (all P &amp;gt; 0.45). Additional sensitivity analyses substantially confirmed these findings. No effect modification by age or gender was observed in these associations. Conclusion In a large cohort of HD patients studied by state-of-the-art 48-hour BP monitoring, the prevalence of isolated diastolic hypertension in HD patients (5.8%) is close to that registered in the general population (6.5%). This alteration predicts the risk for clinical outcomes in unadjusted analyses but not after adjustment for age and sex. Isolated diastolic hypertension is as rare as it is in the general population and unlikely to contribute to the high risk of adverse clinical outcomes in the dialysis population.

#52 Pulmonary hypertension in hemodialysis patients: prevalence and risk factors: a single center study

Abstract Background and Aims Pulmonary hypertension (PH) is an underestimated cardiovascular trouble in patients on hemodialysis (HD). Therefore, we studied its prevalence, risk factors, association with inflammation, and cardiac changes in HD patients. Method This was a single-center cross-sectional observational study conducted at Sfax CNSS polyclinic hemodialysis center during October 2023. Patients on hemodialysis for at least three months were included and divided into those with and without PH; patients with secondary causes for PH were excluded. Clinical characteristics, HD-related factors, lab parameters, and echocardiography details were compared. PH was defined as a mean pulmonary artery pressure (PAP) of &amp;gt; 25 mmHg at rest, and it was further divided as mild (26–39 mmHg), moderate (40–60mmHg), and severe (&amp;gt; 60 mmHg). Mean levels of PAP were compared in different groups according to the main clinical parameters. Results Of 30 patients, 21 patients had PH (mild:15, moderate:4, and two had severe PH) with a prevalence of 70%, and a mean age of 58 years old. No difference was found in clinical characteristics, dialysis-related factors, and biochemical parameters. Inflammation seemed to be more important in the PH group but the difference was not statistically significant (mean C-reactive protein in the PH group vs. 5,69 in the non-PH group; p=0,34). Otherwise, according to echocardiography findings, PAP was significantly higher in patients with left ventricular failure(HF) (mean PAP in HF group vs. 31,12 in the non-HF group; p=0,011), in patients with right ventricular dilation(RVD)(mean PAP in RVD patients=47,83mmHg vs 28,88mmHg in the non-RVD group; p=0,05) and in patients with mitral regurgitation(MR) (mean PAP in MR group=40,18mmHg Vs 28,32mmHg in the non-MR group; p=0,04). Conclusion Haemodialysis patients have a high prevalence of PH, especially in patients with heart failure and ventricular dilation. PH was significantly associated with the presence of mitral regurgitation on echocardiography. Inflammation was slightly higher in PH but our study did not find significant differences in traditional risk factors, and HD-related factors between the groups with and without PH.

Endothelin-1, Extracellular Volume Overload, and Hemodynamics in Hemodialysis Patients.

Extracellular volume (ECV) overload and endothelial cell dysfunction (ECD) are independent risk factors for mortality in hemodialysis patients. Endothelin-1 (ET-1), an endothelium-derived vasoconstrictive peptide, is associated with poor outcomes in hemodialysis patients and heart failure patients without kidney disease. We hypothesized there would be associations between ET-1 and ECV overload assessed with bioimpedance spectroscopy (BIS) in hypertensive hemodialysis patients. We obtained pre-HD plasma ET-1, ECV/weight (using multi-frequency BIS), pre-HD hemodynamic measurements, and ambulatory blood pressure (BP) in a cohort of HD patients. Following appropriate transformations, we conducted correlation and linear regression analyses to identify associations between ET-1 and ECV overload. We further explored associations between ET-1 and total peripheral resistance index (TPRI), cardiac index (CI), and ambulatory BP. Among 66 patients, median ET-1 was 1.93 (1.49-2.56) pg/mL. Median pre-HD ECV/weight, median TPRI, mean CI, and mean systolic ambulatory BP were 0.25 (0.22-0.30) L/kg, 3161 (2711-3642) dynes*sec/cm-5/m2, 2.92 (0.6) L/min/m2, and 143 (14) mmHg, respectively. After reciprocal transformation, ET-1 correlated with reciprocal-transformed ECV/weight (r=0.3, p=.01), log-transformed TPRI (r=-0.3, p=.006), CI (r=0.3, p=.009) and ambulatory BP (r=-0.3, p=.02). Controlling for demographic variables, these associations persisted in linear regression analysis (β=0.15, p=.002; β=-0.8, p=.002; β=0.2, p=.002; β=-19, p=.03). In hypertensive HD patients, ECV overload is associated with ET-1. ET-1 is associated with higher TPRI and lower CI before dialysis and higher ambulatory BP. Further research is necessary to determine if ECV reduction lowers ET-1 or if pharmacologic ET-1 antagonism can improve outcomes in HD patients with refractory ECV overload.

Hemodynamic factors affecting pulmonary hypertension in hemodialysis patients

Hemodynamic factors affecting pulmonary hypertension in hemodialysis patients

Effect of Low and High Sodium Dialysate on Functional Capacity and Health Related Quality of Life in Hemodialysis Patients

Abstract Background Patients on dialysis have low health related quality of life (HRQOL) and an annual mortality rate many-fold greater than the general population. There is uncertainty about whether low sodium in dialysis fluid improves overall health and wellbeing for people on haemodialysis, since there are mixtures of probably good and bad effects. Aim To assess the effect of low sodium and high sodium dialysate on functional capacity and HRQOL in hemodialysis patients. Patients and Methods comparative case-control study conducted on 60 ESRD patients on maintenance hemodialysis receiving their treatment at the Nephrology hemodialysis unit in Luxor International Hospital from June 2021 till November 2021. The study population was divided into 2 groups: Group 1: included 30 patients on low sodium dialysate (130 mmol/l). Group 2: included 30 patients on high sodium dialysate (138 mmol/l). Results Our data revealed a significant increase in the percentage of hypertensive patients recruited to be among the low sodium dialysate group as compared with high sodium group (P value &amp;lt;0.001). At the end of the study, there were a significant decrease in DBP, IDWG and UF among low sodium group compared with high sodium group, there were a significant increase in 6MWT and SF-36 in Low sodium group when compared with High sodium group. No statistical significant difference between the studied groups as regard each of the laboratory data, ECG, and ECHO at the end of the study (P value&amp;gt;0 Conclusion Low sodium dialysate is effective in improving the health related quality of life of hypertensive hemodialysis patients, however, it did not reduce left ventricular mass relative to control despite improving fluid status.

Oculars Pain and Intraocular Hypertension in Hemodialysis Patient with Glaucoma: A Case Report and Review of the Literatures

Resistance hypertension in hemodialysis patient usually is common and sometimes difficult to get achieved target blood pressure control. In patient with intradialytic hypertension, eye pain may occur which can be relate to the severity of the hypertension itself. Hemodialysis has relationship to Intraocular Pressure (IOP). Hemodialysis was be Increased Intraoccular Pressure (IOP) and may be the cause of eye pain during hemodialysis due to ocular dialysis disequilibrium. And this receives inadequate attention by nephrologist as a cause of intradialytic hypertension. In this article, we report a patient with resistant hypertension who complain of right eye pain during and after dialysis. After anterior chamber tapping and the aqueous humor was drained. The symptoms and hypertension improved. Undetected significant increase in IOP during hemodialysis may lead to permanent optic nerve damage and should be recognized as a cause of hypertension. An interesting point of this report was the intraocular hypertension get worsed in hemodialysis patients and could be a cause of resistance hypertension. We suggest regular ophthalmologic evaluation in ESKD (End Stage Kidney Disease) patients should be necessary especially in the patient with poorly controlled hypertension, have previous glaucoma, diabetic retinopathy, eye pain, blurred vision, conjunctivitis and headache.

Prevalence of uncontrolled hypertension in hemodialysis patients: A cross-sectional study from Palestine

Prevalence of uncontrolled hypertension in hemodialysis patients: A cross-sectional study from Palestine

Evaluation of hypertension control among hemodialysis patients in Pakistan: a prospective follow-up study.

Hypertension is highly prevalent and uncontrolled among hemodialysis patients. In Pakistan published data does not provide enough information about the management and factors associated with uncontrolled hypertension in hemodialysis patients. This study was conducted to evaluate the factors influencing the pharmacotherapeutic management and control of hypertension in hemodialysis patients. A prospective follow-up study was conducted on hemodialysis patients who were enrolled at study sites between 1 June 2020 and 31 December 2020. The predialysis blood pressure (BP) readings were recorded as mean SBP and DBP at baseline and for each of 6 months. Multivariate analyses were applied to analyze the factors associated with uncontrolled hypertension in hemodialysis patients. The average predialysis BP (SBP and DBP) of study participants at baseline visit was 158.41 and 87.22 mmHg respectively. After 6 months the study participants have 150.27 mmHg and 80.03 mmHg average predialysis SBP and DBP respectively. Only 28.1% of hemodialysis patients were on target BP after 6 months. Results of multivariate analysis have shown that the use of beta-blockers and calcium channel blockers (CCBs) were significantly associated with hypertension control at baseline [odds ratio (OR) = 1.432, P value = 0.034] (OR = 1.499, P value = 0.045) and at after 6 months (OR = 2.824, P value = 0.015) (OR = 1.883, P value = 0.032). This study revealed that among the antihypertensive drugs, CCBs and beta-blockers provided better management in controlling hypertension among hemodialysis patients.

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients.

Pulmonary hypertension (PH) is a common complication of end-stage renal disease which is associated with adverse outcomes including all-cause mortality and cardiovascular events. Recent studies have demonstrated that Sacubitril/Valsartan (Sac/Val) as an enkephalinase inhibitor and angiotensin II receptor blocker could reduce pulmonary artery systolic pressure (PASP) and improve the prognosis of patients with heart failure. However, whether Sac/Val is effective in hemodialysis (HD) patients with PH is essentially unknown. In this retrospective study, we aimed to evaluate the efficacy and safety of Sac/Val in the treatment of PH in HD patients. A total of 122 HD patients with PH were divided into Sac/Val group (n = 71) and ARBs group (n = 51) based on the treatment regimen. The PASP, other cardiac parameters measured by echocardiography, and cardiac biomarkers including N-terminal fragment of BNP (NT-proBNP) and cardiac troponin I (cTnI) were observed at baseline and 3 months after treatment. There were no significant differences in the baseline characteristics between the two groups. PASP decreased significantly from 45(38, 54) to 28(21, 40) mmHg in Sac/Val group (p < 0.001). PASP reduced from 41(37, 51) to 34(27, 44) mmHg in ARBs group (p < 0.001), and the decrease was more pronounced in the Sac/Val group (p < 0.001). In addition, improvements in the right atrial diameter (RAD), left ventricular diameter (LVD), left ventricular posterior wall thickness (LVPWT), left atrial diameter (LAD), pulmonary artery diameter (PAD), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF), and fractional shortening (FS) were found in Sac/Val group (ps < 0.05). After 3 months, LVD, LAD, LVEDV, LVESV, LVEF, SV, and PASP were significantly improved in Sac/Val group compared with ARBs group (ps <0.05). Significant reduction in NT-proBNP [35,000 (15,000, 70,000) pg/ml vs. 7,042 (3,126, 29,060) pg/ml, p < 0.001] and cTnI [0.056(0.031, 0.085) ng/ml vs. 0.036 (0.012, 0.056) ng/ml, p < 0.001) were observed in Sac/Val group. No significant differences were observed in adverse events between the two groups (ps > 0.05). Sac/Val seems to be an efficacious regimen in PH with favorable safety and has huge prospects for treating PH in HD patients.

Extracellular Volume Overload Is Associated With Increased Endothelin-1 in Hypertensive Hemodialysis Patients

Extracellular Volume Overload Is Associated With Increased Endothelin-1 in Hypertensive Hemodialysis Patients

Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients

BackgroundHyperphosphatemia occurs frequently in end-stage renal disease patients on hemodialysis and is associated with increased mortality. Hyperphosphatemia contributes to vascular calcification in these patients, but there is emerging evidence that it is also associated with endothelial cell dysfunction.MethodsWe conducted a cross-sectional study in hypertensive hemodialysis patients. We obtained pre-hemodialysis measurements of total peripheral resistance index (TPRI, non-invasive cardiac output monitor) and plasma levels of endothelin-1 (ET-1) and asymmetric dimethylarginine (ADMA). We ascertained the routine peridialytic blood pressure (BP) measurements from that treatment and the most recent pre-hemodialysis serum phosphate levels. We used generalized linear regression analyses to determine independent associations between serum phosphate with BP, TPRI, ET-1, and ADMA while controlling for demographic variables, parathyroid hormone (PTH), and interdialytic weight gain.ResultsThere were 54 patients analyzed. Mean pre-HD supine and seated systolic and diastolic BP were 164 (27), 158 (21), 91.5 (17), and 86.1 (16) mmHg. Mean serum phosphate was 5.89 (1.8) mg/dL. There were significant correlations between phosphate with all pre-hemodialysis BP measurements (r = 0.3, p = .04; r = 0.4, p = .002; r = 0.5, p < .0001; and r = 0.5, p = .0003.) The correlations with phosphate and TPRI, ET-1, and ADMA were 0.3 (p = .01), 0.4 (p = .007), and 0.3 (p = .04). In our final linear regression analyses controlling for baseline characteristics, PTH, and interdialytic weight gain, independent associations between phosphate with pre-hemodialysis diastolic BP, TPRI, and ET-1 were retained (β = 4.33, p = .0002; log transformed β = 0.05, p = .005; reciprocal transformed β = -0.03, p = .047).ConclusionsSerum phosphate concentration is independently associated with higher pre-HD BP, vasoconstriction, and markers of endothelial cell dysfunction. These findings demonstrate an additional negative impact of hyperphosphatemia on cardiovascular health beyond vascular calcification.Trial registrationThe study was part of a registered clinical trial, NCT01862497 (May 24, 2013).

Home Blood Pressure monitoring: An economical, reliable, and convenient Tool over ambulatory Blood Pressure monitoring in Patients on Dialysis.

Hypertension and cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients on dialysis. Blood pressure (BP) control is of paramount importance in reducing morbidity and mortality in this high-risk population, although there is no consensus on target BP. Ambulatory BP recording is considered gold standard in estimating the BP among patients on dialysis. But, ambulatory BP recording is cumbersome, not economical, and not easily available to Indian patients. Therefore, an easier and more convenient method has to be implemented to monitor the BP. Some studies demonstrated that home BP recordings may be promising in making a more accurate diagnosis of hypertension in hemodialysis patients. However, there is paucity of research that compares home-based BP monitoring with ambulatory BP recordings in patients on hemodialysis. The present study was thus planned to examine the hypothesis that out-of-dialysis unit BP measurement in the form of home-based measurement of BP is as efficacious as ambulatory BP monitoring (ABPM) in evaluating hypertension among patients on hemodialysis. To assess the accuracy of home-based BP monitoring in comparison to ABPM among chronic kidney disease (CKD) patients on hemodialysis. To assess the ability of home-based BP monitoring to detect hypertension among CKD patients on hemodialysis. This was a prospective observational study carried out in the Department of Medicine in a tertiary care hospital. The total duration of the study was 24 months. Fifty-two CKD patients on hemodialysis fulfilling the eligibility criteria were taken up for the study after informed consent. Blood pressure was measured using a standardized BP measuring equipment at home, thrice a day for 3 days in the interdialysis period. Also, all these patients were subjected to 24 hours of ABPM in the interdialysis period. Home-based BP monitoring records are then compared with the one-time ABPM records. All statistical calculations were done using computer programs Microsoft Excel 2007 (Microsoft Corporation, NY, USA) and SPSS (Statistical Product and Service Solutions; SPSS Inc., Chicago, Illinois, USA) version 21. In our study, the mean awake, asleep, and average ABPM readings of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 141.69/81.33, 139.39/80.04, and 141.23/80.67 mm Hg, respectively, while the mean SBP and DBP recorded on home-based measurements were 143.6 and 82.69 mm Hg, respectively. All the subjects showing mean SBP ≥140 mm Hg as per ABPM had home-based readings of above 140 mm Hg while 23 out of 27 patients (85.2%) with mean SBP &lt;140 mm Hg as per ABPM had similar observation by home-based monitoring (kappa 0.847; p&lt;0.01). All the subjects showing mean DBP ≥90 mm Hg as per ABPM had home-based readings of above 90 mm Hg while 42 out of 44 patients (95.5%) with mean DBP &lt;90 mm Hg as per ABPM had similar observation by home-based monitoring (kappa 0.866; p&lt;0.01). Our study shows that there is no difference between BP readings as observed by ABPM and home-based BP monitoring. Also, home-based BP monitoring can detect hypertension as effectively as ABPM among patients on hemodialysis, thereby making home-based BP monitoring a safe and reliable method of BP measurement in clinical practice.

Role of Antihypertensives in End-Stage Renal Disease: A Systematic Review.

The primary goal of this research is to identify the factors of intradialytic hypertension in hemodialysis patients and stabilize blood pressure (BP) even without antihypertensive medicines. There are various treatment alternatives for lowering BP in these patients, many of which do not require extra pharmacological therapy (e.g. long, slow hemodialysis; short, daily hemodialysis; nocturnal hemodialysis; or, most effectively, dietary salt and fluid restriction in addition to the reduction of dialysate sodium concentration). These parameters provide good monitoring of BP, even with previously diagnosed hypertension. The adjustment of the extracellular volume with a low incidence of intradialytic hypotensive episodes is the most plausible explanation for this outcome.We did a systematic evaluation of all published articles since 1994 to evaluate antihypertensive drug outcomes in hemodialysis patients. All articles were searched in the English language using PubMed and Google Scholar databases. The screening techniques, study selection, data extraction procedures, and risk evaluation of bias were done using specified criteria and overseen by one of the senior writers with the application of quality assessment tools to the final articles. Data were searched using regular and MeSH (Medical Subject Headings) keywords. Although substantial developments have emerged in the medical field, there is still a significant knowledge gap in the sector, particularly when it comes to BP guidelines and therapy choices for hypertensive hemodialysis patients. Until additional data are available, we should treat hypertension in hemodialysis with the use of active pursuit of euvolemia using dry weight probing and reduction of salt excess.

Sex differences in ambulatory blood pressure levels, control and phenotypes of hypertension in hemodialysis patients.

Ambulatory blood pressure (BP) control is worse in men than women with chronic kidney disease or kidney transplantation. So far, no study investigated possible sex differences in the prevalence, control, and phenotypes of BP according to predialysis and 48-h ambulatory blood pressure monitoring (ABPM) in hemodialysis patients. Further, no study has evaluated the diagnostic accuracy of predialysis BP in male and female hemodialysis patients. One hundred and twenty-nine male and 91 female hemodialysis patients that underwent 48-h ABPM were included in this analysis. Hypertension was defined as: (1) predialysis SBP ≥140 or DBP ≥90 mmHg or use of antihypertensive agents, (2) 48-h SBP ≥130 or DBP ≥80 mmHg or use of antihypertensive agents. Predialysis SBP did not differ between groups, while DBP was marginally higher in men. 48-h SBP (137.2 ± 17.4 vs. 132.2 ± 19.2 mmHg, P = 0.045), DBP (81.9 ± 12.1 vs. 75.9 ± 11.7 mmHg, P < 0.001) and daytime SBP/DBP were higher in men. The prevalence of hypertension was not different between groups with the use of predialysis BP or 48-h ABPM (92.2% vs. 89%, P = 0.411). However, concordant lack of control was more frequent in men than women (65.3% vs. 49.4%, P = 0.023). The prevalence of white-coat and masked hypertension did not differ between groups; the misclassification rate with the use of predialysis BP was marginally higher in women. In both sexes, predialysis BP showed low accuracy and poor agreement with ABPM for diagnosing ambulatory hypertension [area-under-the-curve in receiver-operating-curve analyses (SBP/DBP): men, 0.681/0.802, women: 0.586/0.707]. Ambulatory BP levels are higher in male than female hemodialysis patients. Although hypertension prevalence is similar between sexes, men have worse rates of control. The diagnostic accuracy of predialysis BP was equally poor in men and women.

MO902: Age-Specific Impacts of Risk Factors on All-Cause Mortality in Dialysis Patients

Abstract BACKGROUND AND AIMS Chronic haemodialysis patients expect longer lifespan than previously; they have various backgrounds of mortality risk factors. However, age specific impacts of risk factors on mortality in dialysis patients have rarely been evaluated. Therefore, we aimed to analyze age-specific association between risk factors and all-cause mortality and evaluated differences in the association among age groups. METHOD We conducted a post-hoc analysis of the 461 hypertensive chronic haemodialysis (HD) patients participated in the Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) between June 2006 and June 2011. The participants were additionally followed up until 31 July 2018. We stratified the participants into 3 groups (younger patients, n = 156; middle-aged patients, n = 160; elderly patients, n = 145) based on tertile of their ages at their enrollment to the trial. We used age-stratified Cox regression models to assess the association of baseline predictors with all-cause mortality for each age group. In addition, we calculated hazard-ratio based population attributable fraction (PAF) for baseline predictors and all-cause mortality across age groups. RESULTS A median follow-up period of participants was 10.2 years. Means and standard deviations of age for three age groups; younger, middle-aged and elderly patients, were 45.9 ± 6.5, 61.2 ± 3.9 and 72.5 ± 3.3, respectively. The number (%) of deceased patients for the three group was 40 (25.6%), 65 (40.6%) and 106 (73.1%); hazard ratios estimated with Cox regression adjusted for gender and diabetes for the three groups were 1(Reference), 1.43 (0.96–2.14; P = 0.075) and 3.49 (2.41–5.05; P &amp;lt; 0.001), respectively. Age-stratified Cox-regression analyses showed the following associations; diabetes was stably associated with all-cause mortality in all age groups; history of stroke, history of coronary intervention, systolic blood pressure ≥ 170 mmHg and serum phosphate ≥ 6.0 mg/dL had greater impacts on all-cause mortality in younger patients compared with elderly patients; and hypoalbuminemia and hypokalemia had higher impact on all-cause mortality in elderly patients (Figure 1A). We calculated hazard-ratio based PAF for the risk factors to evaluate the difference in impacts of risk factors on all-cause mortality among the age groups; systolic blood pressure ≥ 170mmHg and serum phosphate ≥ 6.0 mg/dL were strongly associated with deaths especially in younger patients (Figure 1B). The total of PAF in elderly patients was almost half of the total of PAF in younger patients. CONCLUSION In chronic haemodialysis patients, associations between risk factors and all-cause mortality are not uniform among different age groups. Vascular disease associated risk factors and hyperphosphatemia were associated with greater risk of morality in younger patients. Hypoalbuminemia and hypokalemia were associated with higher risk of mortality in elderly patients. Proportion of deaths due to modifiable risk factors in elderly HD patients is almost half of that in younger HD patients.

Prevalence and Predictors of Heart Failure among Patients on Maintenance Hemodialysis Therapy at Tertiary Care Hospitals

Background and Aim: The incidence of heart failure among hemodialysis patients predicts poor outcomes. Hypertension, aging, and diabetes mellitus are traditional risk factors for heart failure which may not predict heart failure accurately. Heart failure might be caused by other factors. The present study aims to determine the prevalence and predictors of heart failure among patients on maintenance hemodialysis. Methodology: This cross-sectional study was carried out on 142 hemodialysis patients in the department of Cardiology, PNS Shifa Hospital Karachi and King Abdullah Teaching hospital Mansehra for duration of six months from 5th March 2021 to 4th September 2021. All the patients having age above 16 years and who underwent at least three months of dialysis therapy were enrolled. Patients with severe respiratory distress and mentally incapacitated were excluded. Questionnaire-based Pro-forma was used for collecting patient’s demographic details, clinical details such as human immunodeficiency virus (HIV) disease, heart failure symptoms, hyperlipidemia, angina, and presence of diabetes, etc., and dialysis-related clinical information. Stadiometer and standard weight scale were used for height and post-dialysis weight also known as dry weight respectively. A monthly dose of erythropoietin (EPO) was taken from medical records. Based on the blood sample, albumin, ferritin, urea, complete blood count, C-reactive protein (CRP), and total cholesterol were measured. SPSS version 21 was used for data analysis. Results:Out of 142 hemodialysis patients, 105 (73.9%) were male and 37 (26.1%) were females. Overall mean age was 46.74 ± 11.62 years. Of the total 142 patients, the prevalence of hypertension and diabetes mellitus was 138 (97.2%) and 73 (51.4%) respectively. The incidence of heart failure was 21 (14.8%). The incidence of hypertension, anemia, and angina were heart failure autonomousprognosticators on multivariate analysis. A higher score of malnutrition inflammation and resistance index for erythropoietin was found in heart failure patients. Conclusion: Our study found that heart failure is significantly associated with anemia, angina, and hypertension in hemodialysis patients. Malnutrition–inflammation complex and erythropoietin resistance were more prevalent in patients with heart failure. These conditions necessitate a thorough cardiac evaluation and appropriate treatment. Keywords: Heart Failure, Hemodialysis, Hypertension. Angina

The Relationship Between Pulse Pressure and Hypervolemia in Hemodialysis Patients

Aim: Hypervolemia is a common problem in hemodialysis (HD) patients. Because reaching to optimal&#x0D; dry weight (DW) is difficult. Chronic volume overload causes left ventricular hypertrophy. Therefore,&#x0D; risk of cardiovascular events is very high. High pulse pressure is an indicator of aortic stiffness, an&#x0D; independent risk factor for cardiovascular mortality. Pulse pressure has a strong correlation with systolic&#x0D; blood pressure and thus with myocardial infarction in hypertensive HD patients. Aim of this study is to&#x0D; investigate the relationship between pulse pressure (PP) and hypervolemia.&#x0D; Material and Methods: Seventy (28 male (40%), 42 (60%) female) chronic HD patients with an average&#x0D; of age 48 ± 12 were enrolled. All patients underwent HD 3 times weekly were included. Fluid status&#x0D; [Total Body Water (TBW), ECW and Intracellular Water (ICW) values] was assessed twice (beginning&#x0D; and end of the HD) in HD patients with the body composition monitor (BCM). And blood pressure was&#x0D; measured simultaneously. Before and after hemodialysis, the weight of the patients was measured and&#x0D; recorded.&#x0D; Results: At the beginning of HD, Extracellular Water (ECW) / body weight (BW) (%) was associated&#x0D; systolic blood pressure (SBP) and PP measured simultaneously (P=0.021, P=0.057 respectively).&#x0D; There was no association between diastolic blood pressure with hypervolemia and PP.&#x0D; Conclusion: If patients have hypervolemia especially in the interdialitic period, they have prolonged&#x0D; exposition to cardiovascular risk factors, because hypervolemia is corralated with SBP and PP as well.&#x0D; Both of them are strongly associated with cardiovascular events. Removal of adequate fluid to obtain&#x0D; optimal dry weight causes decrease of systolic and pulse pressure proportionally.

Risk factors affecting intradialytic hypertension in hemodialysis patients

Hemodialysis is a CKD therapy that functions as a kidney replacement. The side effect that often occurs when patients undergoing hemodialysis is intradialytic hypertension (HID), namely an increase in systolic blood pressure &gt;10 mmHg during hemodialysis, due to an increase in cardiac output mediated by volume overload, especially in patients with excess body weight and cardiac dilatation. The objective of this research is to determine the risk factors that influence the occurrence of intradialytic hypertension in CKD patients undergoing hemodialysis at Tugurejo Hospital. Risk factors consist of age, duration of hemodialysis, Quick Blood (blood velocity), ultrafiltration (volume overload), URR. The design used in this research is analytic observational with a cross-sectional approach, the number of respondents is 53 people. The sampling technique used in this research is total sampling. The results showed that age (p-value = &lt; 0.01), duration of hemodialysis (p-value = 0.07), quick blood (p-value = 0.06), ultrafiltration (p-value = 0.04), and URR (p-value = &lt; 0.01) is a protective factor or risk factor for the incidence of intradialytic hypertension. Based on the Spearman rank test, it is known that p-value &gt; means that there is a relationship between age, ultrafiltration and URR with the blood pressure of patients with chronic kidney failure. Age, ultrafiltration, and URR are protective factors or risk factors that influence the incidence of intradialytic hypertension